ReNeuron to unveil results

TEST results for new stem cell techniques that could extend the life of stroke victims will be presented this week ahead of key patient trials in Glasgow.

ReNeuron Group will outline the results of its studies at the UK National Stem Cell Network annual scientific conference in Nottingham.

Strokes are the third largest cause of death in the UK. ReNeuron will announce that its stem cell product has undergone further pre-clinical testing and is working better than expected both in expanding the blood vessels and reducing the in- flammation associated with a stroke.

The firm has gained approval to recruit a dozen patients at Glasgow's Southern General hospital for Phase 1 trials.

Michael Hunt, chief executive of Aim-listed ReNeuron, said: "This data is important as it tells us more about what this cell line is doing as we enter the trials."